Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
104.33
+0.51 (0.49%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 171, with a low estimate of 105 and a high estimate of 216. The average target predicts an increase of 63.90% from the current stock price of 104.33.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 8 | 7 | 7 | 6 | 6 | 7 |
Buy | 6 | 7 | 7 | 8 | 8 | 8 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 14 | 14 | 14 | 14 | 14 | 15 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Jefferies | Jefferies | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +91.70% | Apr 7, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $200 | Strong Buy | Reiterates | $200 | +91.70% | Apr 3, 2025 |
Needham | Needham | Strong Buy Reiterates $153 | Strong Buy | Reiterates | $153 | +46.65% | Apr 1, 2025 |
Mizuho | Mizuho | Buy Maintains $212 → $216 | Buy | Maintains | $212 → $216 | +107.04% | Mar 27, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $200 | Strong Buy | Reiterates | $200 | +91.70% | Mar 6, 2025 |
Financial Forecast
Revenue This Year
631.96M
from 385.69M
Increased by 63.85%
Revenue Next Year
1.04B
from 631.96M
Increased by 63.93%
EPS This Year
-3.30
from -5.99
EPS Next Year
2.19
from -3.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 720.8M | 1.3B | 2.1B | ||
Avg | 632.0M | 1.0B | 1.6B | ||
Low | 547.8M | 764.6M | 1.1B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 86.9% | 110.5% | 100.0% | ||
Avg | 63.9% | 63.9% | 49.7% | ||
Low | 42.0% | 21.0% | 10.6% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.76 | 7.90 | 17.25 | ||
Avg | -3.30 | 2.19 | 10.02 | ||
Low | -4.61 | -3.05 | -0.77 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 686.6% | ||
Avg | - | - | 356.8% | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.